Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) is the third leading fatal cancer worldwide and its incidence continues to increase. Chronic viral hepatitis involving either hepatitis B virus (HBV) or hepatitis C virus (HCV) infection is the leading etiology for HCC, making HCC prevention a major goal of antiviral therapy. While recent clinical observations and translational research have enhanced our understanding of the molecular mechanisms driving the initiation and progression of HCC, much remains unknown. Current data indicates that HCC tumors are highly complex and heterogeneous resulting from the aberrant function of multiple molecular pathways. This complex biology is responsible, at least in part, for the absence of highly efficient target-directed therapies for this deadly cancer. Additionally, the direct or indirect effect of HBV and HCV infection on the development of HCC is still a contentious issue. Thus, the question remains whether viral hepatitis-associated HCC stems from virus-specific factors, and/or from a general mechanism involving inflammation and tissue regeneration. In this review we summarize general mechanisms implicated in HCC, emphasizing data generated by new technologies available today. We also highlight specific pathways by which HBV and HCV could be involved in HCC pathogenesis. However, improvements to current in vitro and in vivo systems for both viruses will be needed to rigorously define the temporal sequence and specific pathway dysregulations that drive the strong clinical link between chronic hepatitis virus infection and HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140 · cited 4×
“This observation, as well as differences in HCC susceptibility across different HBV genotypes (genotype C conferring the greatest risk for HCC) [4,52] and specific viral mutations associated with increased risk for HCC [53,54], strongly imply a direct viral effect on HCC development (Fig.”
BackgroundInfluentialGender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
Luedde, T., & Schwabe, R. F. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.213 · Cited by 1,345
Okuda, M., Li, K., Beard, M. R., Showalter, L. A., Scholle, F., Lemon, S. M., & Weinman, S. A. (2002) · Gastroenterology · doi:10.1053/gast.2002.30983 · Cited by 926
White, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766
Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin
Ding, Q., Xia, W., Liu, J.-C., Yang, J.-Y., Lee, D.-F., Xia, J., Bartholomeusz, G., Li, Y., Pan, Y., Li, Z., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.009 · Cited by 597
Control of cccDNA function in hepatitis B virus infection
Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., & Dandri, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.022 · Cited by 552 · cited 1×
“Following binding to its receptor and entry into the cell, the viral nucleocapsid releases the viral DNA, that is transferred to the nucleus where it is converted into a covalently closed circular DNA (cccDNA) minichromosome (reviewed in [34] and Fig.”
Background
Cited by
Liu, J., Fan, L., Yu, H., Zhang, J., He, Y., Feng, D., Wang, F., Li, X., Liu, Q., Li, Y., et al. (2019) · Hepatology · doi:10.1002/hep.30607 · Cited by 449
Fu, Y., Liu, S., Zeng, S., & Shen, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1396-4 · Cited by 390
The yin and yang of evasion and immune activation in HCC
Makarova-Rusher, O. V., Medina-Echeverz, J., Duffy, A. G., & Greten, T. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.038 · Cited by 293
Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma
D'souza, S., Lau, K. C., Coffin, C. S., & Patel, T. R. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i38.5759 · Cited by 257
Weil, M. M., Ray, F. A., Genik, P. C., Yu, Y., McCarthy, M., Fallgren, C. M., & Ullrich, R. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104819 · Cited by 83
Wang, J., Chen, X., Wu, D., Jia, C., Lian, Q., Pan, Y., & Yang, J. (2024) · Liver Research · doi:10.1016/j.livres.2024.11.001 · Cited by 18
Metadata
- Authors
- Shlomai, A., de Jong, Y. P., & Rice, C. M.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 26
- Pages
- 78-88
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2128227067
- Cited by
- 177
- References
- 11
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.